Results 21 to 30 of about 60,957 (246)
Hematology/Oncology and Stem Cell Therapy, 2021 Primary myelofibrosis (PMF) is a subtype of BCR-ABL1 negative myeloproliferative neoplasm. Its characteristic features include clonal myeloproliferation, dysregulation of kinase signaling pathway, abnormal release of cytokines leading to fibrosis in the ...
Farhan Khalid +4 more
doaj +1 more source
A JAK of all trades: how global phosphoproteomics reveal the Achilles heel of MPNs
Molecular & Cellular Oncology, 2021 While Janus-kinase (JAK)-inhibitors effectively reduce the inflammatory phenotype of myeloproliferative neoplasms (MPN), they do not affect disease burden or presence of the mutated clone to a major extent. Here, we show how Janus-kinase 2 (JAK2)-mutated
Tina M. Schnoeder +2 more
doaj +1 more source
Britannin suppresses MCF-7 breast cancer cell growth by inducing apoptosis and inhibiting autophagy [PDF]
Avicenna Journal of PhytomedicineObjective: Breast cancer is the main reason for cancer-related death in women. Britannin is a sesquiterpene lactone compound derived from Inula aucheriana with anti-tumor properties. We aimed to explore the impacts of britannin on apoptosis and autophagy
Sadegh Rajabi +3 more
doaj +1 more source
Myeloproliferative neoplasms: From JAK2 mutations discovery to JAK2 inhibitor therapies
Oncotarget, 2011 Most BCR-ABL1-negative myeloproliferative neoplasms (MPN) carry an activating JAK2 mutation. Approximately 96% of patients with polycythemia vera (PV) harbors the V617F mutation in JAK2 exon 14, whereas the minority of JAK2 (V617F)-negative subjects shows several mutations in exon 12. Other mutation events as MPL, TET2, LNK, EZH2 have been described in
PASSAMONTI, FRANCESCO +3 more
openaire +4 more sources
JAK2, STAT3 Gene Polymorphisms in Turkish Patients with Behçet’s Disease
Gazi Medical JournalObjective: Behçet’s disease (BD) is a chronic, multisystemic inflammatory disorder with an unknown etiology. T cells are crucial in the pathogenesis of BD.
Darya Farhoomand Aksoy +3 more
doaj +1 more source
PLoS ONE, 2022 JAK2 is cytokine-activated non-receptor tyrosine kinase. Although JAK2 is mainly localized at the plasma membrane, it is also present on the centrosome. In this study, we demonstrated that JAK2 localization to the centrosome depends on the SH2 domain and
Aashirwad Shahi +3 more
doaj +1 more source
Enu mutagenesis identifies a novel platelet phenotype in a loss-of-function Jak2 allele. [PDF]
PLoS ONE, 2013 Utilizing ENU mutagenesis, we identified a mutant mouse with elevated platelets. Genetic mapping localized the mutation to an interval on chromosome 19 that encodes the Jak2 tyrosine kinase.
Nicole M Anderson +16 more
doaj +1 more source
JAK2 Negative Polycythemia Vera
Journal of Laboratory Physicians, 2010 ABSTRACTPolycythemia vera (PV) is a stem cell disorder, characterized as a panhyperplastic, malignant, and neoplastic marrow disorder. Several reasons suggest that a mutation on the Janus kinase-2 gene (JAK2) is the most probable candidate gene involved in PV pathogenesis, as JAK2 is directly involved in intracellular signaling, following its exposure ...
Geetha, J P +3 more
openaire +2 more sources
CALRETICULIN IN MYELOPROLIFERATIVE NEOPLASMS: THE OTHER SIDE OF THE ALICE MIRROR [PDF]
European Medical Journal Hematology, 2014 Calreticulin (CALR), a Ca2+ binding protein mostly localised in the endoplasmic reticulum, regulates Ca2+ homeostasis, chaperones, and other proteins to the nucleus and other cellular compartments.
Lilian Varricchio, Anna Rita Migliaccio
doaj
Loss of Jak2 selectively suppresses DC-mediated innate immune response and protects mice from lethal dose of LPS-induced septic shock. [PDF]
PLoS ONE, 2010 Given the importance of Jak2 in cell signaling, a critical role for Jak2 in immune cells especially dendritic cells (DCs) has long been proposed.
Jixin Zhong +6 more
doaj +1 more source